Regeneron Pharmaceuticals (REGN) Profit After Tax (2009 - 2026)

Regeneron Pharmaceuticals' Profit After Tax history runs 18 years deep, the most recent figure standing at -$65.6 million for Q1 2026.

• On a quarterly basis, Profit After Tax fell 107.76% year-over-year to -$65.6 million in Q1 2026; TTM through Mar 2026 was -$865.8 million, a 29.51% increase from a year earlier, with the FY2025 full-year figure at $85.4 million, up 16.99% from the prior year.
• Profit After Tax grew to -$65.6 million in Q1 2026 per REGN's latest filing, from -$3.7 billion in the prior quarter.
• Across five years, Profit After Tax topped out at $1.5 billion in Q3 2025 and bottomed at -$3.7 billion in Q4 2025.
• The 5-year median for Profit After Tax is $968.4 million (2023), against an average of $405.3 million.
• Across the five-year window, Profit After Tax plunged 395.09% in 2024 and surged 18963.01% in 2025, its largest moves.
• Year by year, Profit After Tax stood at $1.2 billion in 2022, then retreated by 3.13% to $1.2 billion in 2023, then plunged by 395.09% to -$3.4 billion in 2024, then decreased by 6.72% to -$3.7 billion in 2025, then jumped by 98.2% to -$65.6 million in 2026.
• Per Business Quant, the three latest REGN Profit After Tax figures stand at -$65.6 million (Q1 2026), -$3.7 billion (Q4 2025), and $1.5 billion (Q3 2025).